Pre- and Post- Influenza Human Sera Panels
Closed Solicitation Posted
- Solicitation number
- 75D30124Q77727
- Agency
- CDC Office of Acquisition Services Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q515 Medical- Pathology
- Place of performance
- Atlanta, Georgia 30329, United States
- Points of contact
-
- Jennifer Gartzke xuy7@cdc.gov (404) 498-0020
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services' Centers for Disease Control and Prevention (CDC) is seeking to procure anonymous serum samples from six age cohorts (young pediatric, older pediatric, adolescent, adult, older adult, and elderly) to evaluate the ability of current influenza vaccine strains to induce protective antibodies against newly circulating influenza virus strains. The contractor will collect blood samples from each individual before and 21-28 days after receiving the current, seasonal influenza vaccine. For the young pediatric and older pediatric participants who require two vaccine doses, the post-vaccination samples will be collected after the second dose. The contract also requires the provision of large volume post-vaccination serum samples from some adult participants for use in further testing.
This is a full and open competition solicitation with a NAICS code of 621511 - Medical Laboratories. Responses are due by August 7, 2024. The contract has a one-year base period and four one-year option periods. The place of performance is Atlanta, Georgia.
Notice text
2 versions
Update #2 · Latest ·
Amendment 00001 is being issued to:
1. Add questions and answers.
2. Add the SF1449.
3. Add the SF30.
The due date for quotes is not being extended.
Update #1 ·
The purpose of this contract is for the provision of anonymous serum samples from six age cohorts (young pediatric, older pediatric, adolescents, adult, older adults, and elderly) with each individual providing blood prior to administration of the specified current, seasonal influenza vaccine (S1) and again 21 to 28 days after immunization (S2). For young pediatric populations (ages 6 months to 35 months) and older pediatrics who require two doses of influenza vaccines, the S2 blood will be collected 21 to 28 days after the second dose of influenza vaccine. Serum samples will be tested for vaccine-induced antibodies to determine if the current influenza vaccine strains induce protective levels of antibodies against newly circulating influenza virus strains.
This contract is also for the provision of large volume S2 samples from some of the adult participants for use in hemagglutination inhibition assays with virus isolates and characterization of immune responses following influenza vaccination.
Attachments
| File | Type | Posted |
|---|---|---|
| Amendment_00001_RFQ_75D30124Q777727.pdf | ||
| 75D30124Q77727_QandA.docx | DOCX document | |
| A19_SF1449 - POST.docx | DOCX document | |
| A19_Combined SynSol_Post_Final.docx | DOCX document |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity